Shopping Cart
- Remove All
Your shopping cart is currently empty
(9)
Apoptosis Filter
Apoptosis Tyrosine Kinase/AdaptorsACK1
(6)
ALK
(80)
BTK
(93)
Bcr-Abl
(83)
CSF-1R
(20)
DYRK
(30)
Discoidin Domain Receptor (DDR)
(12)
EGFR
(368)
Ephrin Receptor
(21)
FAK
(55)
FGFR
(131)
FLT
(117)
HER
(72)
Hck
(5)
IGF-1R
(65)
IGF-2R
(2)
JAK
(191)
PDGFR
(117)
PKA
(76)
PYK2
(9)
ROS Kinase
(22)
Src
(126)
Syk
(38)
TAM Receptor
(51)
Tie-2
(11)
Trk receptor
(60)
Tyrosine Kinases
(63)
VEGFR
(261)
c-Fms
(48)
c-Kit
(90)
c-Met/HGFR
(110)
c-RET
(43)
c-RET
c-RET, a proto-oncogene located on the long arm of chromosome 10, is a member of the cadherin superfamily and encodes a receptor tyrosine kinase that acts as a signal for cell surface molecules to be converted for cell growth and differentiation. The activation of RET protein will activate downstream signaling pathways (including RAS, MAPK, ERK, PI3K, AKT, etc.), leading to cell proliferation, migration and differentiation.
Lenvatinib
Cited
T0520417716-92-8
Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4 5.2 nM). Lenvatinib has strong anti-tumor activity.
- 38 €
Size
QTY
CitedVepafestinib
T94452129515-96-2
Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].
- 125 €
Size
QTY
Regorafenib Cited
T1792755037-03-7
Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.
- 28 €
Size
QTY
CitedPralsetinib
TQ02772097132-94-8
Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion).
- 34 €
Size
QTY
Cabozantinib Cited
T2586849217-68-1
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035 1.3 4.6 7 11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
- 37 €
Size
QTY
CitedSelpercatinib Cited
T82222152628-33-4
Selpercatinib (LOXO-292) is a tyrosine kinase inhibitor with antineoplastic properties, displaying IC50 values of 14.0 nM for RET (WT), 24.1 nM for RET (V804M), and 530.7 nM for RET (G810R).
- 28 €
Size
QTY
CitedPz-1
T125981800505-64-9
Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.
- 28 €
Size
QTY
Lenvatinib mesylate Cited
T8541857890-39-2
Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
- 32 €
Size
QTY
CitedSGI-7079
T69821239875-86-5
SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistance.
- 33 €
Size
QTY
BT-13
T10624924537-98-4
BT-13 is a selective agonist of glial cell line-derived neurotrophic factor (GDNF) receptor RET independently of GFLs. BT-13 promotes neurite growth from sensory neurons in vitro.
- 34 €
Size
QTY
Fedratinib Cited
T1995936091-26-8
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
- 42 €
Size
QTY
CitedDanusertib Cited
T2094827318-97-8
Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed.
- 51 €
Size
QTY
CitedAD80 Cited
T43011384071-99-1
AD80, a multikinase inhibitor, targets RET, RAF, SRC, and S6K with significantly reduced activity on mTOR.
- 37 €
Size
QTY
CitedSPP-86
T169231357349-91-7
SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.
- 38 €
Size
QTY
PF 477736
T6028952021-60-2
PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
- 42 €
Size
QTY
Ilorasertib
TQ00591227939-82-3
Ilorasertib (ABT-348) (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A Aurora B Aurora C (IC50s: 120 nM 7 nM 1 nM). It also suppresses RET tyrosine kinase, PDGFRβ, and Flt1 (IC50s: 7 nM, 3 nM, and 32 nM).
- 31 €
Size
QTY
Agerafenib
T20701188910-76-0
Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.
- 33 €
Size
QTY
Regorafénib N-oxyde (M2)
T10157835621-11-9
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib, a multi-target inhibitor for VEGFR1 2 3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13 4.2 46, 1.5, 22, 7, and 2.5 nM).
- 35 €
Size
QTY
TG101209
T3065936091-14-4
TG101209 is a selective JAK2 inhibitor with an IC50 of 6 nM.
- 38 €
Size
QTY
Regorafenib monohydrate
T1792L1019206-88-2
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respectively.
- 28 €
Size
QTY
TPX-0046
T353842359650-19-2
TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.
- 150 €
Size
QTY
Compound TPX-0046
T677792411115-73-4
Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.
- 72 €
Size
QTY
ENMD-2076
T2358934353-76-1
ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR VEGFR2, Flt4 VEGFR3, FGFR1, FGFR2, Src, PDGFRα.
- 44 €
Size
QTY
Enbezotinib
T622852359649-81-1
Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.
- 116 €
Size
QTY
Treprostinil Sodium
T5171289480-64-4
Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6 1.9 6.2 nM).
- 44 €
Size
QTY
Amuvatinib Cited
T2516850879-09-3
Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
- 41 €
Size
QTY
CitedGSK3179106
T54911627856-64-7
GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nM
- 33 €
Size
QTY
AST 487 Cited
T4053630124-46-8
AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
- 29 €
Size
QTY
CitedRPI-1
T2282269730-03-2
RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
- 44 €
Size
QTY
Regorafenib Hydrochloride
T8402835621-07-3
Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- 28 €
Size
QTY
RET V804M-IN-1
T84672414909-94-5
RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).
- 30 €
Size
QTY
BBT594
T7418882405-89-2
BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.
- 35 €
Size
QTY
WHI-P180
T2032211555-08-7
WHI-P180 (Janex 3) is a potent inhibitor of EGFR and Cdk2, with IC50 values of 4.0 µM and 1.0 µM, respectively.
- 37 €
Size
QTY
G-749
T26201457983-28-6
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
- 38 €
Size
QTY
ON123300
T69201357470-29-1
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4 Ark5 PDGFRβ FGFR1 RET Fyn (IC50: 3.9 5 26 26 9.2 11 nM).
- 37 €
Size
QTY
DUN73423
T696442414373-42-3
DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.
- 45 €
Size
QTY
TG-89
T20742936091-56-4In house
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.
- 32 €
Size
QTY
JNJ-38158471
T22349951151-97-6
JNJ-38158471 (CS-2660), a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, inhibits closely related tyrosine kinases such as Ret and Kit with IC50 of 180 nM and 500 nM.
- 45 €
Size
QTY
RET-IN-23
T790992479961-46-9
RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.
- 278 €
Size
QTY
RET-IN-3
T96732414374-53-9
RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.
- 90 €
Size
QTY
TAS05567
T169951429038-15-2
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM), showing >70% inhibition of Syk and four other kinases [FLT3 (IC50: 10 nM), JAK2 (IC50: 4.8 nM), KDR (IC50: 600 nM), RET (IC50: 29 nM)] in a panel of 192 kinases.
- 1.871 €
Size
QTY
trans-Pralsetinib
T108232097132-93-7
trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).
- 79 €
Size
QTY
Agerafenib hydrochloride
T149281227678-26-3
Agerafenib hydrochloride, a highly potent inhibitor of BRAFV600E (Kd: 14 nM), demonstrates significant efficacy.
- 1.586 €
Size
QTY
Go to page 1
Page of 1
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.